G005819

LC/MS (TOF) Analysis of Antiarrhythmic Drugs and Metabolites on Ascentis^® Express HILIC: Improvement in Analyte Response after Solid Phase Extraction (SPE) using HybridSPE^®-Phospholipid

application for HPLC, application for SPE

属性

• 技術: HPLC: suitable; solid phase extraction (SPE): suitable
• 測試參數: sample preparation: SPE (Solid Phaes Extraction); sample: rat plasma was spiled directly from stock standard to a level of 400 ng/mL; SPE tube/cartridge: HybridSPE-Phospholipid 96-Well Plate, 50 mg/2 mL (575656-U); sample addition: apply 100 μL of plasma to plate, followed by 300 μL of 1% formic acid acetonitrile. Agitate via vortex for 4 min; elution: place on vacuum manifold and apply 10" Hg vacuum for 4 minutes. Collect filtrate and analyze directly.; column: Ascentis Express HILIC, 10 cm x 2.1 mm I.D., 2.7 μm particles (53939-U); mobile phase: [A] 5 mM ammonium formate; [B] 5 mM ammonium formate in acetonitrile; (5:95, A:B, pH 7.0 with formic acid); flow rate: 0.4 mL/min; pressure: 1305 psi (90 bar); column temp.: 35 °C; detector: ESI(+), full scan, m/z 100-1000; injection: 0.5 μL; sample: plasma extract, analyte concentration of final sample work-up is equivalent to 100 ng/mL
• 適合性: application for HPLC; application for SPE
• 應用: clinical

说明

分析報告

The basic characteristics of antiarrhythmic cardiac drugs and associated metabolites make them targets for HILIC chromatographic separation. HILIC mobile phases consist of a high composition of acetonitrile which facilitates the direct analysis of precipitated plasma samples without the need for additional sample solvent exchange. In most cases, the high organic mobile phase also increases analyte response with ESI(+) MS detection. This application used HybridSPE-Phospholipid sample prep to remove phospholipids and precipitated proteins prior to LC/MS analysis on Ascentis Express HILIC. These chromatograms compare the response with HybridSPE-Phospholipid vs. standard protein precipitation sample prep methods. The highest grade solvents provided clean, robust operation. Cerilliant CRMs provided reliable quantification.

法律資訊

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

分析物

Amiodarone hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®
N-Desethylamiodarone hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®
Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®
(±)-Flecainide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®